ATE464062T1 - Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi - Google Patents
Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpiInfo
- Publication number
- ATE464062T1 ATE464062T1 AT04021066T AT04021066T ATE464062T1 AT E464062 T1 ATE464062 T1 AT E464062T1 AT 04021066 T AT04021066 T AT 04021066T AT 04021066 T AT04021066 T AT 04021066T AT E464062 T1 ATE464062 T1 AT E464062T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical composition
- acid
- liquid pharmaceutical
- amino acid
- arginine
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 title abstract 5
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 title abstract 5
- 150000003839 salts Chemical group 0.000 abstract 8
- 235000001014 amino acid Nutrition 0.000 abstract 7
- 150000001413 amino acids Chemical class 0.000 abstract 7
- 239000004475 Arginine Substances 0.000 abstract 6
- 235000009697 arginine Nutrition 0.000 abstract 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 239000002253 acid Substances 0.000 abstract 5
- 239000002585 base Substances 0.000 abstract 5
- 230000015572 biosynthetic process Effects 0.000 abstract 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
- 239000004472 Lysine Substances 0.000 abstract 3
- 150000007513 acids Chemical class 0.000 abstract 3
- 235000003704 aspartic acid Nutrition 0.000 abstract 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000012458 free base Substances 0.000 abstract 3
- 235000013922 glutamic acid Nutrition 0.000 abstract 3
- 239000004220 glutamic acid Substances 0.000 abstract 3
- 235000018977 lysine Nutrition 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 239000006172 buffering agent Substances 0.000 abstract 2
- 239000012669 liquid formulation Substances 0.000 abstract 2
- 239000001384 succinic acid Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15769699P | 1999-10-04 | 1999-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE464062T1 true ATE464062T1 (de) | 2010-04-15 |
Family
ID=22564882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00968584T ATE345810T1 (de) | 1999-10-04 | 2000-10-03 | Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide |
| AT04021066T ATE464062T1 (de) | 1999-10-04 | 2000-10-03 | Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00968584T ATE345810T1 (de) | 1999-10-04 | 2000-10-03 | Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US6525102B1 (de) |
| EP (2) | EP1491208B1 (de) |
| JP (2) | JP2003510368A (de) |
| CN (2) | CN1245216C (de) |
| AT (2) | ATE345810T1 (de) |
| AU (2) | AU783306B2 (de) |
| BR (2) | BR0014486A (de) |
| CA (2) | CA2386228A1 (de) |
| CZ (2) | CZ20021186A3 (de) |
| DE (2) | DE60044213D1 (de) |
| ES (1) | ES2276698T3 (de) |
| HU (3) | HU0800692D0 (de) |
| IL (3) | IL149008A0 (de) |
| NO (2) | NO20021567L (de) |
| NZ (2) | NZ529856A (de) |
| PL (2) | PL211886B1 (de) |
| PT (1) | PT1491208E (de) |
| WO (1) | WO2001024814A1 (de) |
Families Citing this family (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7006874B2 (en) * | 1996-01-05 | 2006-02-28 | Thermage, Inc. | Treatment apparatus with electromagnetic energy delivery device and non-volatile memory |
| JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| IL149008A0 (en) * | 1999-10-04 | 2002-11-10 | Chiron Corp | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| SK11142002A3 (sk) * | 1999-12-30 | 2004-09-08 | Chiron Corporation | Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2 |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| EP1935431A3 (de) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2 |
| JP4147234B2 (ja) * | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、カートリッジ及び吐出装置 |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| EP1378236B1 (de) * | 2001-03-23 | 2007-06-27 | Ajinomoto Co., Inc. | Mittel gegen stressinduzierte krankheiten |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| DE10149030A1 (de) * | 2001-10-05 | 2003-04-10 | Viscum Ag | Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin |
| PL374506A1 (en) | 2001-10-15 | 2005-10-31 | Chiron Corporation | Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| US7842668B1 (en) | 2001-11-13 | 2010-11-30 | Genentech, Inc. | Apo-2 ligand/trail formulations |
| IL161812A0 (en) * | 2001-11-13 | 2005-11-20 | Genentech Inc | Apo2 ligand/trail formulations |
| DK1478394T3 (da) * | 2002-02-27 | 2008-10-13 | Immunex Corp | Stabiliseret TNFR-Fc formulation med arginin |
| EP3210624A1 (de) * | 2002-02-27 | 2017-08-30 | Immunex Corporation | Stabilisierte tnfr-fc-zusammensetzung mit arginin |
| US6964778B1 (en) * | 2002-09-06 | 2005-11-15 | Health Research, Inc. | Temperature controlled content release from liposomes |
| US6991805B1 (en) * | 2002-09-06 | 2006-01-31 | Health Research, Inc. | Temperature sensitive control of liposome-cell adhesion |
| JP5057648B2 (ja) * | 2002-09-26 | 2012-10-24 | 塩野義製薬株式会社 | 安定化されたタンパク組成物 |
| EP1803445A3 (de) * | 2003-01-08 | 2007-11-21 | Novartis Vaccines and Diagnostics, Inc. | Stabilisierte lyophilisierte Zubereitungen mit Gewebefaktor-Inhibitor (TFPI) oder Varianten des Gewebefaktor-Inhibitors |
| ES2311789T3 (es) * | 2003-01-08 | 2009-02-16 | Novartis Vaccines And Diagnostics, Inc. | Composiciones liofilizadas estabilizadas que comprenden inhibidor de la via del factor tisular o variantes del inhibidor de la via del factor tisular. |
| JP2006515882A (ja) * | 2003-01-08 | 2006-06-08 | カイロン コーポレイション | 組織因子経路インヒビター（ｔｆｐｉ）または組織因子経路インヒビター改変体を含有する安定化水性組成物 |
| US20040208869A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Uses of anti-integrin alphanubeta3 antibody formulations |
| US20040208870A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| EP1610765B1 (de) * | 2003-03-31 | 2008-08-13 | ALZA Corporation | Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden |
| DK2335725T3 (en) | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
| US7445933B2 (en) * | 2003-07-16 | 2008-11-04 | Abbott Laboratories, Inc. | Stable calibrators or controls for measuring human natriuretic peptides |
| US7291501B2 (en) * | 2003-07-16 | 2007-11-06 | Abbott Laboratories | Stable compositions for measuring human natriuretic peptides |
| CA2535562A1 (en) * | 2003-08-13 | 2005-03-03 | Chiron Corporation | Improved method of purifying tfpi and tfpi analogs |
| US7141544B2 (en) | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
| DE10348550A1 (de) * | 2003-10-20 | 2005-06-16 | Hexal Biotech Forschungsgmbh | Stabile wässrige G-CSF-haltige Zusammensetzungen |
| KR101403910B1 (ko) | 2003-11-04 | 2014-06-09 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 길항제 항-ｃｄ４０ 단클론성 항체 및 그것의 사용 방법 |
| US20050136542A1 (en) * | 2003-12-19 | 2005-06-23 | Beckman Coulter, Inc. | Stabilized liquid reference solutions |
| US8338374B2 (en) * | 2003-12-23 | 2012-12-25 | Pharmacia Corporation | Stable growth hormone liquid formulation |
| US20070184050A1 (en) * | 2003-12-25 | 2007-08-09 | Kirin Beer Kabushiki Kaisha | Stable water-based medicinal preparation containing antibody |
| TW200538148A (en) * | 2004-01-13 | 2005-12-01 | Vasogenix Pharmaceuticals Inc | Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same |
| US20090023644A1 (en) * | 2004-01-13 | 2009-01-22 | Southard Jeffery L | Methods of using cgrp for cardiovascular and renal indications |
| US7976847B2 (en) * | 2004-01-13 | 2011-07-12 | Vasogenix Pharmaceuticals, Inc. | Controlled release CGRP delivery composition for cardiovascular and renal indications |
| WO2005110059A2 (en) * | 2004-03-17 | 2005-11-24 | Chiron Corporation | Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) |
| JP2007531738A (ja) | 2004-04-02 | 2007-11-08 | アムジエン・インコーポレーテツド | ＩＬ−１ｒａの凝集を低下させる方法 |
| CN1993139B (zh) * | 2004-06-01 | 2011-02-16 | 阿雷斯贸易股份有限公司 | 稳定的干扰素液体制剂 |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| DE102004059776A1 (de) * | 2004-09-17 | 2006-04-06 | Deutsches Zentrum für Luft- und Raumfahrt e.V. | Brennstoffzellensystem |
| JP4147235B2 (ja) * | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置 |
| ATE542920T1 (de) * | 2004-12-22 | 2012-02-15 | Ambrx Inc | Modifiziertes menschliches wachstumshormon |
| US20060188555A1 (en) * | 2005-01-21 | 2006-08-24 | Micheal Cormier | Therapeutic peptide formulations with improved stability |
| CN100337684C (zh) * | 2005-05-11 | 2007-09-19 | 北京双鹭药业股份有限公司 | 一种胸腺五肽的水溶液制剂、其制备方法及应用 |
| CN100342909C (zh) * | 2005-05-11 | 2007-10-17 | 北京双鹭药业股份有限公司 | 一种胸腺素α1的水溶液制剂、其制备方法及应用 |
| CN100336557C (zh) * | 2005-05-11 | 2007-09-12 | 北京双鹭药业股份有限公司 | 一种生长抑素的水溶液制剂、其制备方法及应用 |
| US7964200B2 (en) | 2005-05-18 | 2011-06-21 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against Chlamydia infection |
| KR100769709B1 (ko) * | 2005-05-31 | 2007-10-23 | 주식회사 대웅 | 인성장호르몬을 함유하는 안정한 액상 제제 |
| WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| US20070191271A1 (en) * | 2006-02-10 | 2007-08-16 | Dow Pharmaceutical Sciences | Method for stabilizing polypeptides lacking methionine |
| WO2007103425A2 (en) * | 2006-03-06 | 2007-09-13 | Novartis Ag | Kits and methods for preparing pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| CN101426817B (zh) | 2006-04-21 | 2013-07-10 | 诺华有限公司 | 拮抗性抗-cd40抗体药物组合物 |
| CN105363022A (zh) * | 2006-07-06 | 2016-03-02 | 株式会社大熊 | 稳定的人生长激素液体制剂 |
| CN101505789A (zh) * | 2006-07-06 | 2009-08-12 | 株式会社大熊 | 稳定的人生长激素液体制剂 |
| US7923425B2 (en) * | 2006-08-21 | 2011-04-12 | Henkel Ag & Co. Kgaa | Low-foaming, acidic low-temperature cleaner and process for cleaning surfaces |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| US7951368B2 (en) * | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| US20100189721A1 (en) * | 2007-07-06 | 2010-07-29 | Smithkline Beecham Corporation | Antibody formulations |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| NZ586590A (en) | 2008-01-09 | 2012-06-29 | Sanofi Aventis Deutschland | Insulin analogues or derivatives having an extremely delayed time-action profile |
| US10058593B2 (en) | 2008-03-26 | 2018-08-28 | Oramed Ltd. | Methods and compositions for oral administration of proteins |
| LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
| CA2742988A1 (en) * | 2008-11-17 | 2010-05-20 | Genentech, Inc. | Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
| AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| KR101853606B1 (ko) * | 2009-07-06 | 2018-05-03 | 사노피-아벤티스 도이칠란트 게엠베하 | 메티오닌을 함유하는 수성 인슐린 제제 |
| US20120121580A1 (en) * | 2009-07-28 | 2012-05-17 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| RU2568831C2 (ru) | 2009-07-28 | 2015-11-20 | Шайр Хьюман Дженетик Терапиз | Композиции и способы для лечения болезни гоше |
| CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| CA2780554C (en) * | 2009-11-17 | 2017-08-15 | Ipsen Pharma S.A.S. | Formulation for hgh and rhigf-1 combination |
| WO2011088120A1 (en) | 2010-01-15 | 2011-07-21 | Amgen Inc. | Antibody formulation and therapeutic regimens |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| EA201892184A1 (ru) | 2010-03-01 | 2019-03-29 | БАЙЕР ХЕЛЬСКЕР ЛЛСи | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора |
| US20130136733A1 (en) * | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| CN103249401B (zh) | 2010-09-15 | 2016-01-20 | 兰德尔·J·米斯尼 | 使用细菌毒素衍生的转运序列递送生物活性剂的系统和方法 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| US9321848B2 (en) | 2011-06-28 | 2016-04-26 | Leukocare Ag | Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide |
| WO2013030160A1 (en) | 2011-08-29 | 2013-03-07 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| JP6171331B2 (ja) * | 2012-12-25 | 2017-08-02 | 東ソー株式会社 | Ｆｃ結合性タンパク質の精製方法および定量方法 |
| EP4215205A1 (de) * | 2013-01-03 | 2023-07-26 | Oramed Ltd. | Verfahren und zusammensetzungen zur behandlung von nafld, lebersteatose und folgen davon |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| AR095399A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones con oxidación reducida, método |
| US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
| PT2968467T (pt) * | 2013-03-13 | 2020-07-28 | Hoffmann La Roche | Formulações de oxidação reduzida |
| JP2016513478A (ja) | 2013-03-15 | 2016-05-16 | ジェネンテック， インコーポレイテッド | 細胞培養培地及び抗体を産生する方法 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| JP2014062100A (ja) * | 2013-11-05 | 2014-04-10 | Glaxosmithkline Llc | 抗体処方 |
| EP3091995B1 (de) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilisierte pharmazeutische formulierungen von insulin aspart |
| US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| JP6735674B2 (ja) | 2014-01-09 | 2020-08-05 | サノフイＳａｎｏｆｉ | インスリンアスパルトの安定化された医薬製剤 |
| US10260111B1 (en) | 2014-01-20 | 2019-04-16 | Brett Eric Etchebarne | Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample |
| PT3139965T (pt) | 2014-05-07 | 2021-12-27 | Applied Molecular Transp Llc | Moléculas de fusão derivadas de toxinas cholix para administração oral de carga biologicamente ativa |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| MX391067B (es) | 2014-10-01 | 2025-03-21 | Eagle Biologics Inc | Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad. |
| MA41138B1 (fr) | 2014-12-12 | 2023-07-31 | Sanofi Aventis Deutschland | Formulation à rapport fixe d'insuline glargine/lixisenatide |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP6247241B2 (ja) * | 2015-02-27 | 2017-12-13 | ノバルティス アーゲー | 抗体処方 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| DK3287139T3 (da) * | 2015-04-21 | 2021-09-13 | Beijing Staidson Medical Tech Co Ltd | Nervevækstfaktorsammensætning og injektionspulver |
| BR112018010945A2 (pt) | 2015-12-30 | 2018-12-04 | Genentech Inc | formulações com degradação de polissorbato reduzida |
| WO2018038301A1 (en) * | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| US20180110856A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical Formulations and Methods of Making the Same |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
| US20210137809A1 (en) * | 2017-06-14 | 2021-05-13 | Biosolution Co., Ltd | Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p |
| JP7626369B2 (ja) * | 2017-08-08 | 2025-02-07 | ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト | ヘモペキシン製剤 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| SI3762009T1 (sl) | 2018-03-08 | 2023-03-31 | Applied Molecular Transport Inc. | Iz toksinov izpeljani dostavni konstrukti za peroralno dostavo |
| WO2019173787A1 (en) | 2018-03-08 | 2019-09-12 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| CA3103603A1 (en) | 2018-06-13 | 2019-12-19 | Akron Biotechnology, LLC. | Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions |
| US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
| CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
| IL294461A (en) * | 2020-01-13 | 2022-09-01 | Aptevo Res & Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| KR102545250B1 (ko) * | 2020-03-31 | 2023-06-21 | 한미약품 주식회사 | 신규한 면역 활성 인터루킨 2 아날로그 |
| CN116940358A (zh) | 2021-01-12 | 2023-10-24 | 度勒科特公司 | 持续释放药物递送系统和有关的方法 |
| CA3211539A1 (en) * | 2021-03-11 | 2022-09-15 | Boris Schwartsburd | Liquid formulations comprising mutant fgf-21 peptide pegylated conjugates |
| CN117120070B (zh) * | 2021-03-11 | 2024-11-15 | 89生物公司 | 包含突变型fgf-21肽peg化缀合物的液体制剂 |
| AU2023367497A1 (en) | 2022-10-26 | 2025-05-15 | Nihon Medi-Physics Co., Ltd. | Radioactive pharmaceutical composition |
| AU2024231427A1 (en) * | 2023-03-09 | 2025-09-04 | Merck Sharp & Dohme Llc | Formulations comprising actriia polypeptide variants |
| CN117883376B (zh) * | 2024-03-14 | 2024-06-25 | 北京四环生物制药有限公司 | 含重组人白细胞介素-2的药物制剂及其制备方法 |
| CN118593451B (zh) * | 2024-08-08 | 2024-10-15 | 卡瑞济(北京)生命科技有限公司 | 一种包含l-精氨酸的抗肿瘤药物及其制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| JPS60215631A (ja) * | 1984-04-09 | 1985-10-29 | Takeda Chem Ind Ltd | インタ−ロイキン−２組成物 |
| EP0158487B1 (de) | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stabile Interleukin-2-Zusammensetzung |
| US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
| US5034225A (en) * | 1985-12-17 | 1991-07-23 | Genentech Inc. | Stabilized human tissue plasminogen activator compositions |
| JPH0645551B2 (ja) * | 1986-01-07 | 1994-06-15 | 塩野義製薬株式会社 | インタ−ロイキン−２組成物 |
| US4894226A (en) | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
| US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| EP0303746B2 (de) * | 1987-08-21 | 1998-12-02 | Mallinckrodt Group Inc. | Stabilisierung von Wachstumshormonen |
| US4883661A (en) | 1987-10-09 | 1989-11-28 | Daly John M | Use of arginine as an lymphokine synergist |
| US5078997A (en) * | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
| DE4111393A1 (de) * | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| FR2684878B1 (fr) | 1991-12-12 | 1994-02-11 | Roussel Uclaf | Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation. |
| IL107887A (en) * | 1992-12-08 | 2003-07-06 | Ambi Inc | Stabilized lanthionine containing bacteriocin compositions |
| US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| ATE216590T1 (de) | 1995-02-06 | 2002-05-15 | Genetics Inst | Arzneimittelformulierungen für il-12 |
| US5888968A (en) * | 1995-06-07 | 1999-03-30 | Chiron Corporation | TFPI formulation |
| DE69637012T2 (de) | 1995-06-07 | 2009-01-08 | G.D. Searle Llc (N.D.Ges.D. Staates Delaware) | Waessrige Formulierung enthaltend TFPI und Lösungsvermittlers |
| SI1516628T1 (sl) * | 1995-07-27 | 2013-10-30 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
| CN1142940C (zh) * | 1996-10-04 | 2004-03-24 | 安姆根有限公司 | 含有mpl配体的药物组合物 |
| EP1005551A2 (de) * | 1997-01-31 | 2000-06-07 | Human Genome Sciences, Inc. | Inhibitor 3 des gewebefaktor-weges. |
| PT1069912E (pt) | 1998-04-03 | 2007-09-14 | Novartis Vaccines & Diagnostic | Formulações injectáveis de igf contendo succinato como agente tampão |
| IL149008A0 (en) * | 1999-10-04 | 2002-11-10 | Chiron Corp | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| EP1282438B1 (de) * | 2000-05-10 | 2005-08-03 | Novo Nordisk Health Care AG | Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen |
| IL155002A0 (en) * | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| US20020147184A1 (en) * | 2001-01-26 | 2002-10-10 | Schering Corporation | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
-
2000
- 2000-10-03 IL IL14900800A patent/IL149008A0/xx unknown
- 2000-10-03 PL PL370852A patent/PL211886B1/pl not_active IP Right Cessation
- 2000-10-03 HU HU0800692A patent/HU0800692D0/hu unknown
- 2000-10-03 JP JP2001527813A patent/JP2003510368A/ja active Pending
- 2000-10-03 BR BR0014486-0A patent/BR0014486A/pt not_active Application Discontinuation
- 2000-10-03 CZ CZ20021186A patent/CZ20021186A3/cs unknown
- 2000-10-03 CA CA002386228A patent/CA2386228A1/en not_active Abandoned
- 2000-10-03 CA CA2477857A patent/CA2477857C/en not_active Expired - Lifetime
- 2000-10-03 AT AT00968584T patent/ATE345810T1/de not_active IP Right Cessation
- 2000-10-03 HU HU0401975A patent/HU227347B1/hu unknown
- 2000-10-03 EP EP04021066A patent/EP1491208B1/de not_active Expired - Lifetime
- 2000-10-03 WO PCT/US2000/027156 patent/WO2001024814A1/en not_active Ceased
- 2000-10-03 DE DE60044213T patent/DE60044213D1/de not_active Expired - Lifetime
- 2000-10-03 DE DE60031999T patent/DE60031999T2/de not_active Expired - Lifetime
- 2000-10-03 HU HU0203133A patent/HUP0203133A3/hu unknown
- 2000-10-03 PT PT04021066T patent/PT1491208E/pt unknown
- 2000-10-03 AU AU78475/00A patent/AU783306B2/en not_active Ceased
- 2000-10-03 CN CNB008163286A patent/CN1245216C/zh not_active Expired - Fee Related
- 2000-10-03 PL PL00354987A patent/PL354987A1/xx not_active Application Discontinuation
- 2000-10-03 US US09/677,643 patent/US6525102B1/en not_active Expired - Fee Related
- 2000-10-03 NZ NZ529856A patent/NZ529856A/en unknown
- 2000-10-03 CZ CZ2004-1041A patent/CZ305123B6/cs not_active IP Right Cessation
- 2000-10-03 EP EP00968584A patent/EP1220682B1/de not_active Expired - Lifetime
- 2000-10-03 BR BRPI0017437A patent/BRPI0017437B8/pt not_active IP Right Cessation
- 2000-10-03 AT AT04021066T patent/ATE464062T1/de not_active IP Right Cessation
- 2000-10-03 NZ NZ535205A patent/NZ535205A/en not_active IP Right Cessation
- 2000-10-03 ES ES00968584T patent/ES2276698T3/es not_active Expired - Lifetime
- 2000-10-03 CN CNB2004100858470A patent/CN100389821C/zh not_active Expired - Lifetime
-
2002
- 2002-04-03 NO NO20021567A patent/NO20021567L/no not_active Application Discontinuation
- 2002-04-04 IL IL149008A patent/IL149008A/en active IP Right Grant
- 2002-11-18 US US10/299,039 patent/US7030086B2/en not_active Expired - Fee Related
-
2004
- 2004-10-15 NO NO20044406A patent/NO20044406L/no not_active Application Discontinuation
- 2004-10-29 JP JP2004317319A patent/JP2005068158A/ja active Pending
-
2005
- 2005-12-05 US US11/293,379 patent/US20060093598A1/en not_active Abandoned
- 2005-12-05 US US11/293,322 patent/US7807142B2/en not_active Expired - Fee Related
-
2006
- 2006-01-13 AU AU2006200141A patent/AU2006200141B2/en not_active Ceased
-
2007
- 2007-12-18 IL IL188230A patent/IL188230A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60044213D1 (de) | Stabilisierte flüssige pharmazeutische Zusammensetzung enthaltend TFPI | |
| ES2561658T3 (es) | Derivados de GLP-1 con doble acilación | |
| UY27320A1 (es) | Nuevas composiciones farmacéuticas | |
| TR200200252T2 (tr) | Şimerik polipeptidler, bunların üretimi için yöntem ve kullanımı | |
| MXPA03007358A (es) | Transportadores que contienen porciones de arginina separadas. | |
| CA2402191A1 (en) | Use of insulin for the treatment of cartilagenous disorders | |
| WO1997007794A1 (en) | Composition for local anesthesia | |
| ES2184310T3 (es) | Formulacion autoemulsionante para compuestos lipofilos acidos. | |
| PT1589949E (pt) | Composições liofilizadas estabilizadas compreendendo inibidor da coagulação por factores tecidulares ou variante de inibidor da coagulação por factores tecidulares | |
| CA2480226A1 (en) | Stable pharmaceutical composition containing factor viii | |
| DK1588707T3 (da) | Stabilt fast medicinsk præparat til oral administration af ramosetron | |
| EA200401298A1 (ru) | Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение | |
| BR0211060A (pt) | Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano | |
| DE60042831D1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
| TW200833321A (en) | Pharmaceutical composition for treating hypertension, diabetes mellitus and cardiovascular diseases | |
| FR2846883B1 (fr) | Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide | |
| BR9908479A (pt) | Composições farmacêuticas que contêm o inibidor de fosfolipase [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil_-1h-indol- 4-il]óxil] acetato de sódio | |
| WO2003026582A3 (en) | Method of preparing phenoxy alkanoic, alkenoic, and alkynoic acids and salts thereof via a dicarboxylate intermediate | |
| KR950024769A (ko) | 고농도 tcf 제제 | |
| DE69918098D1 (de) | Neue suesstoffzusammensetzungen | |
| DE69208171D1 (de) | Gallensäuren enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe | |
| KR900014429A (ko) | 폴리펩티드 유도체 및 칼슘 대사 향진제 | |
| IT1307866B1 (it) | Composizioni farmaceutiche contenenti inibitori dell'ormone dellacrescita o loro frammenti biologicamente attivi per il trattamento | |
| TH45966A3 (th) | แอนตี้ฮิสตามีน ไซรัปที่เสถียร | |
| JPH04270227A (ja) | ヒト組織プラスミノーゲン活性化因子含有組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |